Which CRDMO Is Good at Protein Degradation?



San Diego, California May 18, 2026 (Issuewire.com) - Key Takeaways

- An idealCRO for protein degradation combines discovery biology, medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), and development expertise within an integrated platform.
- WuXi AppTec helps innovators advance targeted protein degrader programs through coordinated discovery technologies, chemistry expertise, and scalable development support.
- As targeted protein degradation expands across oncology, immunology, and other disease areas, integrated partners can help reduce delays, improve decisions, and accelerate progression to clinic.

Introduction

Which CRO is good at protein degradation? As targeted protein degradation (TPD) becomes one of the most active areas in drug discovery, this question is increasingly relevant for biotech and pharmaceutical innovators.

Unlike traditional small molecules that inhibit protein function, TPD therapies remove disease-causing proteins by leveraging the cell's natural degradation machinery, such as the ubiquitin–proteasome system. This creates new opportunities to address targets that were previously difficult to drug.

However, developing degraders such as Proteolysis Targeting Chimeras and molecular glues is more complex than conventional small-molecule discovery. Success often requires expertise across biology, medicinal chemistry, DMPK, analytical sciences, formulation, and manufacturing.

For this reason, an ideal CRO for protein degradation is usually one that can connect these functions in a unified model. WuXi AppTec is one example of a partner supporting targeted protein degrader

programs from discovery through manufacturing.

What Makes a CRO Strong in Targeted Protein Degradation?

Protein degrader programs create scientific and operational challenges that many conventional outsourcing models are not designed to solve.

A degrader molecule often needs to coordinate interactions among a target protein, linker, and E3 ligase ligand to form a productive ternary complex. Potency alone is not enough. Developers must also optimize degradation efficiency, selectivity, permeability, solubility, metabolic stability, and in vivo exposure.

That means a strong CRO for protein degradation should provide:

- **Integrated Biology and Chemistry:** Biologists and chemists need to work together early so medicinal chemistry decisions align with assay results, target biology, and biomarker strategy.
- **Fast Design–Make–Test–Analyze Cycles:** Because degrader structure–activity relationships (SAR) can be nonlinear, rapid iteration is essential. Programs often require simultaneous optimization of multiple variables rather than a traditional sequential process.
- **Experience with Complex Chemistry:** Degraders may involve bifunctional molecules, macrocycles, chiral centers, or linker architectures that require advanced synthesis expertise.
- **Multi-Parameter Optimization:** The idealpartners evaluate potency together with PK, selectivity, manufacturability, and translational potential.
- **Development Readiness:** Programs benefit from early consideration of process chemistry, formulation, analytical methods, and scale-up feasibility.

In short, an ideal CRO for targeted protein degradation is not just a synthesis vendor; it is a scientific partner.

How Does WuXi AppTec Support Protein Degrader Development?

WuXi AppTec supports targeted protein degrader programs through an integrated CRDMO model connecting discovery, development, and manufacturing.

Targeted protein degraders can be more complex than traditional small molecules because successful candidates may require simultaneous optimization of degradation activity, ternary complex formation, selectivity, permeability, metabolic stability, and scalable synthesis.

At the discovery stage, WuXi AppTec combines chemistry and biology to help accelerate hit identification and lead optimization. This may include degrader design, linker strategy, E3 ligase ligand optimization, protein degradation assays, target engagement studies, and rapid refinement of SAR.

As Dr. Tao Guo, Senior Vice President, Research Chemistry Services, Integrated Program Management at WuXi AppTec, noted, discovery chemistry is increasingly evolving into a highly integrated function working alongside biology from the beginning of programs.

As programs advance, WuXi AppTec also supports chemistry, manufacturing, and controls (CMC) development and drug metabolism and pharmacokinetics (DMPK) studies to help improve manufacturability, bioavailability, and clinical readiness. Capabilities may include process optimization, analytical development, formulation strategies, and evaluation of drug exposure, tissue distribution,

metabolic pathways, and PK/PD relationships.

By connecting discovery, chemistry, DMPK, and manufacturing, WuXi AppTec can help innovators make faster decisions and more efficiently advance degrader programs from concept to clinic.

Why Do Innovators Choose Integrated Partners for Protein Degrader Programs?

Many degrader programs face delays not because of weak science, but because discovery, DMPK, toxicology, CMC, and manufacturing are often spread across multiple vendors. This can delay timelines, duplicate work, and complicate decision-making.

Integrated partners help reduce these challenges by connecting key stages of development. Promising compounds can move more efficiently from discovery into development without repeated handoffs or loss of technical context.

Shared data across chemistry, biology, and PK teams can improve prioritization, identify liabilities earlier, and reduce late-stage surprises. This is especially important for degraders, where potency alone may not predict overall success.

Manufacturability is another key factor. Some degrader molecules present synthetic complexity, formulation hurdles, or scale-up risks that become visible later. Early assessment can save time and cost.

For emerging biotech companies with limited internal infrastructure, integrated partners such as WuXi AppTec can provide coordinated support from early discovery through later-stage development.

Conclusion: Which CRO Is Good at Protein Degradation?

An ideal CRO for protein degradation is one that combines biology, chemistry, DMPK, and downstream development expertise in a connected platform.

Because targeted protein degrader development is more complex than traditional small-molecule programs, innovators increasingly need partners that can solve both scientific and operational challenges.

WuXi AppTec stands out through its integrated approach to helping innovators advance targeted protein degrader programs—from early degrader design to process optimization and clinical readiness.

As targeted protein degradation continues to expand across multiple disease areas, capable and science-driven CRO partners are likely to play an increasingly important role.

FAQ

Which CRO is good at protein degradation?

A strong CRO for protein degradation typically combines biology, chemistry, DMPK, and development expertise in one integrated model. WuXi AppTec is one example.

What is targeted protein degradation?

A therapeutic strategy that removes disease-causing proteins by directing them to the cell's natural degradation machinery.

Why are proteolysis targeting chimeras and molecular glue programs challenging?

They often require simultaneous optimization of ternary complex formation, selectivity, PK properties, and manufacturability.

Why does integration matter in degrader drug discovery?

Integrated teams can reduce delays, improve decisions, and align discovery with development earlier.

How does WuXi AppTec support targeted protein degrader development?

WuXi AppTec supports targeted protein degrader development through discovery biology, medicinal chemistry, DMPK, CMC development, and manufacturing within an end-to-end CRDMO model.

Media Contact

WuXi AppTec

*********@wuxiapptec.com

https://www.wuxiapptec.com/

Source : WuXi AppTec